| Factor Information | |
|---|---|
| Data ID | 518 |
| Factor | glutathione S-transferase mu1 (GSTM1) expression |
| Description | GSTM1 belongs to the superfamily of glutathione-S-transferases, which can metabolize a broad range of reactive oxygen species (ROS) and degradation xenobiotics. glutathione S-transferase mu1 (GSTM1) expression was significantly decreased in the irreversible CHD-PAH group (all P<0.05) |
| Biomarker | YES |
| Classification | E2 (physiological factor - biochemical index) |
| Association | |
|---|---|
| Application | prognosis |
| Objective | decreased in the irreversible CHD-PAH group |
| p Value | <0.05 |
| Conclusion | Upregulated caveolin-1, filamin A, and cathepsin D combined with increased macrophagocytes and downregulated GSTM1 may be potential biomarkers and targets in the irreversibility CHD-PAH, and which may be useful in evaluating the operability and understanding the irreversibility of CHD-PAH. Expression of these pathological biomarkers combined with pathological changes in lung biopsy may have great value in predicting the irreversibility of PAH. |
| Risk Factor | unknown |
| CHD Type | |
|---|---|
| ID | 465 |
| CHD Type | isolated CHD/non-isolated CHD |
| CHD Subtype | ASD/VSD/VSD, PFO/other |
| Reference | |
|---|---|
| PMID | 29480151 |
| Year | 2018 |
| Title | Potential biomarkers and targets in reversibility of pulmonary arterial hypertension secondary to congenital heart disease: an explorative study. |
| Sample | ||
|---|---|---|
| Population | All | |
| Source | follow-up | |
| Region | Beijing, China | |
| Method | mean pulmonary arterial pressures, mass-spectrometry analysis, immunohistochemistry, western blot, Proteomic analysis | |
| Race | Asian | |
| Disease History | N/A | |
| Treatment History | repair surgery | |
| Group | irreversible CHD-PAH group, mPA ≥25 mmHg(Treatment) | reversible CHD-PAH group, mPAP < 25 mmHg(Control) |
| Number | 4 | 10 |
| Age | 46.3±14.5 (31-65) years | 27.1±19.7 (4-59) years |
| Gender (Male: Female) | 2:2 | 5:5 |
| Marker Level | iTRAQ-ratio (Irr:Con)=0.023 iTRAQ-ratio (Irr:Rev)=0.033 iTRAQ-ratio (Irr:Rev)=0.631 | N/A |
